Literature DB >> 10571012

Leukocyte adhesion deficiency type II.

D J Becker1, J B Lowe.   

Abstract

Leukocyte adhesion deficiency type II (LAD II) is a rare disorder characterized by recurrent infections, persistent leukocytosis, and severe mental and growth retardation. LAD II neutrophils are deficient in expression of selectin ligand activity, and exhibit a correspondingly diminished ability to roll on endothelium and to traffic to inflammatory sites in vivo. LAD II patients exhibit a deficiency in the expression of cell surface fucosylated glycan structures that include the H and Lewis blood group determinants and the sialyl Lewis x epitope, yet the corresponding fucosyltransferase activities responsible for synthesis of these structures are expressed at normal levels. The molecular defect in LAD II has been localized to the pathway that synthesizes GDP-fucose from GDP-mannose. However, the two known component enzymes in this GDP-fucose biosynthetic pathway are normal in sequence and in expression levels in LAD II cells. The genetic lesion in LAD II that accounts for the generalized fucosylation defect in LAD II patients remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571012     DOI: 10.1016/s0925-4439(99)00071-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

Review 1.  Golgi nucleotide sugar transport and leukocyte adhesion deficiency II.

Authors:  C B Hirschberg
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Pathways and bottlenecks in the web of inflammatory adhesion molecules and chemoattractants.

Authors:  K Ley
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats.

Authors:  Evelyn Jantscher-Krenn; Monica Zherebtsov; Caroline Nissan; Kerstin Goth; Yigit S Guner; Natasha Naidu; Biswa Choudhury; Anatoly V Grishin; Henri R Ford; Lars Bode
Journal:  Gut       Date:  2011-12-03       Impact factor: 23.059

4.  Notch deficiency implicated in the pathogenesis of congenital disorder of glycosylation IIc.

Authors:  Hiroyuki O Ishikawa; Shunsuke Higashi; Tomonori Ayukawa; Takeshi Sasamura; Motoo Kitagawa; Kenichi Harigaya; Kazuhisa Aoki; Nobuhiro Ishida; Yutaka Sanai; Kenji Matsuno
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

5.  Predicting the Retention Behavior of Specific O-Linked Glycopeptides.

Authors:  Majors J Badgett; Barry Boyes; Ron Orlando
Journal:  J Biomol Tech       Date:  2017-08-04

Review 6.  Developmental diseases caused by impaired nucleotide sugar transporters.

Authors:  Li Liu; Carlos B Hirschberg
Journal:  Glycoconj J       Date:  2012-04-17       Impact factor: 2.916

7.  Neural and synaptic defects in slytherin, a zebrafish model for human congenital disorders of glycosylation.

Authors:  Yuanquan Song; Jason R Willer; Paul C Scherer; Jessica A Panzer; Amy Kugath; Emmanuel Skordalakes; Ronald G Gregg; Gregory B Willer; Rita J Balice-Gordon
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

8.  Substrate specificities and availability of fucosyltransferase and beta-carotene hydroxylase for myxol 2'-fucoside synthesis in Anabaena sp. strain PCC 7120 compared with Synechocystis sp. strain PCC 6803.

Authors:  Mari Mochimaru; Hajime Masukawa; Takashi Maoka; Hatem E Mohamed; Wim F J Vermaas; Shinichi Takaichi
Journal:  J Bacteriol       Date:  2008-08-15       Impact factor: 3.490

Review 9.  Targeting selectins and selectin ligands in inflammation and cancer.

Authors:  Steven R Barthel; Jacyln D Gavino; Leyla Descheny; Charles J Dimitroff
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

10.  Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.

Authors:  Lianchun Wang; Jillian R Brown; Ajit Varki; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.